-34%

est. 2Y upside i

HealthcareSeries B

Debut is building the future of beauty with cutting-edge AI and biotechnology, creating high-performing, innovative ingredients and formulations that propel the industry forward. The company specializes in scientifically-discovered, clinically-proven and inherently sustainable ingredients that provide maximum efficacy.

Rank

#776

Sector

Biotechnology, Beauty, Synthetic Biology

Est. Liquidity

~3Y

Data Quality

Data: Medium

Debut is a promising Series B company with a strong competitive moat driven by its AI-powered biotech platform and strategic partnerships with industry giants like L'Oréal.

Last updated: March 10, 2026

Bull (35%)+250%

Debut's AI-driven platform rapidly discovers and commercializes multiple blockbuster ingredients across beauty, fragrance, and food, securing significant market share from traditional chemical suppliers. Strategic partnerships with L'Oréal and other major brands expand globally, pushing revenue to $300M+ by 2028 and justifying a $2.1B valuation at 7x revenue.

Base (45%)+50%

Debut successfully scales its core beauty ingredient business, maintaining strong partnerships and launching a few successful fragrance and food ingredients. It establishes itself as a niche leader in sustainable biotech ingredients, growing 30-40% YoY to ~$150M revenue by 2028 and achieving a $900M valuation at 6x revenue.

Bear (20%)-60%

Increased competition from incumbents like BASF and Givaudan, who invest heavily in similar biotech R&D, erodes Debut's market share and pricing power. Regulatory hurdles or slower-than-expected adoption of novel ingredients limit growth, leading to revenue stagnation at ~$50M and a down round to $240M, significantly impacting common stock value given the preference stack.

Est. time to liquidity~3.0 years

Preference Stack Risk

high

Debut has raised $126M in total funding, which represents 21% of the estimated $600M post-money valuation, indicating a meaningful liquidation preference ahead of common shareholders.

Dilution Risk

high

As a Series B company, Debut will likely require at least one or two more funding rounds before an exit, leading to further dilution for common stock holders.

Secondary Liquidity

none

There is no public information suggesting active secondary markets or tender offers for Debut's shares at this stage.

View all 3 open roles at Debut →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Debut's data — designed to show you've done your homework.

  • 1

    “Given L'Oréal's repeated investment and partnership, how is Debut leveraging this relationship to accelerate market penetration and defend against other large incumbents like BASF or Givaudan who might develop similar biotech capabilities?”

  • 2

    “With a composite TAM of $17.1B and a SAM of $500M, what are the key milestones and revenue targets Debut aims to achieve in the next 24 months to significantly expand its SAM and capture a larger share of the overall market?”

  • 3

    “As a Series B company with significant capital raised, how does Debut envision the path to a liquidity event (IPO or acquisition) within the next 2-4 years, and what are the company's plans for managing employee equity dilution in future funding rounds?”

Community

Valuation Sentiment

Our model estimates -34% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.